flow-cytometry
(2)
ImpriMed, Inc.
ImpriMed is a Palo Alto-based precision medicine company using live-cell drug sensitivity testing and AI to predict how individual cancer patients - starting with dogs and cats - will respond to specific chemotherapy drugs. Founded in 2017 by Stanford engineering PhDs Sungwon Lim and Jamin Koo, ImpriMed serves a network of 250+ veterinary oncologists and is expanding its platform into human blood cancers and pharma CRO services.
LASE Innovation Inc.
LASE Innovation Inc. is a Boston-area techbio company commercializing LP™ Optical Cell Barcoding, a laser-particle technology that tags individual cells with narrowband light signatures tuned across more than 1,000 wavelengths. Spun out of the Wellman Center at Massachusetts General Hospital and MIT, the platform lets researchers run multiple passes of flow cytometry on the same sample, track the same cells over time, and connect single-cell data across flow, imaging and sequencing. The company is turning a long-standing limitation of flow cytometry - that you generally read a cell once and lose it - into a repeatable, trackable measurement.